U.S. regulators approved the first GLP-1 weight-loss pill—a tablet formulation of Novo Nordisk’s NOVO.B5.00%increase; green up pointing triangle Ozempic and Wegovy—ushering in a new era of the obesity ...

Good news for those of us in chilly climates: Staying warm has never looked more chic. The ultimate topper—the winter hat—has the power to transform an outfit entirely, and right now, several beloved ...

Losing weight has officially become more convenient. The popular GLP-1 obesity treatment Wegovy is now available as a once-daily pill. On Monday evening, the Food and Drug Administration approved Novo ...

Food and Drug Administration (FDA) Commissioner Marty Makary on Monday denied recent reports suggesting plans for his agency to add a black box warning to COVID-19 vaccines. CNN reported last week ...

Dec 18 (Reuters) - Japan's Takeda Pharmaceutical (4502.T), opens new tab said on Thursday its experimental pill for a type of skin disease, developed using artificial intelligence, succeeded in two ...

The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk’s weight-loss drug Wegovy, introducing a new option for how patients can take medicines in a class of drugs ...

The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy, according to pharmaceutical giant Novo Nordisk. It is the first pill of its kind to receive ...

Some tout a daily semaglutide pill as a game-changer for weight-loss treatment. The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo ...

The agency greenlit an oral version of the obesity drug Wegovy. By Dani Blum The Food and Drug Administration on Monday approved a pill version of the weight-loss injectable drug Wegovy, offering ...

The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Wegovy pill, as it’s called, is first oral version of a GLP-1 drug that ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk’s ...